Solifenacin (VESIcare) is an antimuscarinic medication approved for overactive bladder with urge urinary incontinence, urgency, and urinary frequency. It is widely used in California OAB treatment, including in San Diego, and has the distinction of also being FDA-approved in combination with mirabegron (VESICARE LS with mirabegron) for adult OAB patients when a single agent provides insufficient control.
How Solifenacin Works
Solifenacin selectively blocks M3 muscarinic receptors — the subtype most responsible for bladder contractions. Compared to some older antimuscarinics, its M3 selectivity may offer somewhat better bladder targeting, though system-wide effects still occur because M3 receptors are present throughout the body.
Evidence for OAB in California Patients
Clinical trials show solifenacin reduces urgency episodes, urge incontinence events, daytime frequency, and nocturia versus placebo. Dose flexibility (5mg and 10mg tablets) allows San Diego providers to titrate based on response and tolerability.
Side Effects
Dry mouth and constipation are the most common side effects, occurring in a meaningful percentage of patients. Like all antimuscarinics, solifenacin carries cognitive side effect concerns with long-term use — a SUFU white paper found a likely small but significant increased dementia risk with chronic anticholinergic OAB medications. This is particularly relevant for older California patients.
Combination Therapy with Mirabegron
For San Diego patients who have partial response to solifenacin alone, the combination of solifenacin 5mg plus mirabegron offers an alternative to stepping up to a higher antimuscarinic dose — potentially achieving better OAB control with fewer side effects than a higher solifenacin dose alone.
When OAB Medications Aren't Enough
If solifenacin — alone or combined — has not provided adequate OAB relief or has caused intolerable side effects, California Bladder offers advanced treatment options at our San Diego area locations. Call (858) 571-3630.
This article is for informational purposes only and does not constitute medical advice. Coverage information is general; individual plan requirements vary. A clinical evaluation is required.